STOCK TITAN

MariMed Inc. (MRMD) CEO settles RSUs, 10,612 shares withheld for taxes

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MARIMED INC. President and CEO Jon R. Levine reported on July 15, 2026 the vesting and settlement of 30,625 restricted stock units into common stock and a related 10,612-share tax-withholding disposition. Following these transactions, he directly holds 21,358,631 common shares, with 91,875 RSUs remaining under the grant that will vest in three equal installments on October 15, 2026, January 15, 2027 and April 15, 2027. An additional 6,684,640 shares are held in a family trust for his spouse and children, for which he disclaims beneficial ownership.

Positive

  • None.

Negative

  • None.
Insider Levine Jon R
Role President and CEO
Type Security Shares Price Value
Exercise Restricted Stock Units (RSU) F1, F4 30,625 $0.00 $0.00
Exercise Common stock F1 30,625 $0.00 $0.00
Tax Withholding Common stock F2 10,612 $0.0662 $702.51
holding Common stock F3 -- -- --
Holdings After Transaction: Restricted Stock Units (RSU) — 91,875 shares (Direct); Common stock — 21,358,631 shares (Direct); Common stock — 6,684,640 shares (Indirect, By the Jon Levine Family Trust)
Footnotes (4)
  1. F1. RSUs convert to shares of common stock on a one-for-one basis.
  2. F2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
  3. F3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  4. F4. The RSUs were granted on April 15, 2026; the remaining RSUs under this grant will vest in three equal installments on each of October 15, 2026, January 15, 2027 and April 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
RSUs converted to common shares 30,625 shares Restricted stock units converted to common stock on July 15, 2026
Shares withheld for taxes 10,612 shares Common shares withheld to satisfy tax obligations on July 15, 2026
Direct common shares held 21,358,631 shares Direct holdings of Jon R. Levine after reported transactions
Unvested RSUs remaining 91,875 RSUs RSU balance from April 15, 2026 grant after July 15, 2026 vesting
Family trust shares 6,684,640 shares Shares held by the Jon Levine Family Trust; beneficial ownership disclaimed
Tax withholding price $0.0662 per share Per-share value used for the 10,612-share tax-withholding disposition
Restricted Stock Units (RSU) financial
"The RSUs were granted on April 15, 2026; the remaining RSUs..."
tax withholding obligations financial
"withheld by the Issuer to satisfy tax withholding obligations in connection..."
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these securities..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"beneficial owner of these securities for purposes of Section 16..."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider equity transactions did MariMed (MRMD) report for Jon R. Levine on July 15, 2026?

MariMed President and CEO Jon R. Levine reported the conversion of 30,625 RSUs into common stock and a related 10,612-share disposition to cover tax withholding obligations, all dated July 15, 2026, as part of his equity compensation activity.

How many MariMed (MRMD) shares does Jon R. Levine hold after these transactions?

After the reported transactions, Jon R. Levine directly holds 21,358,631 common shares of MariMed. A further 6,684,640 shares are held in a family trust for his spouse and children, for which he formally disclaims beneficial ownership under securities rules.

What RSU balance and vesting schedule does Jon R. Levine have at MariMed (MRMD)?

Following the July 15, 2026 vesting, Jon R. Levine has 91,875 RSUs remaining from an April 15, 2026 grant. These RSUs will vest in three equal installments on October 15, 2026, January 15, 2027 and April 15, 2027, subject to the award agreement.

What was the tax-withholding share disposition for Jon R. Levine at MariMed (MRMD)?

To satisfy tax withholding obligations tied to RSU vesting, 10,612 common shares were withheld by MariMed at a price of $0.0662 per share. This disposition is coded as a tax payment transaction rather than an open-market sale of shares.

How are family-trust holdings treated in Jon R. Levine’s MariMed (MRMD) ownership disclosures?

An indirect holding of 6,684,640 common shares is reported as held by the Jon Levine Family Trust for his spouse and children. Levine disclaims beneficial ownership of these securities, meaning he does not concede economic or voting control for Section 16 purposes.

Were Jon R. Levine’s MariMed (MRMD) equity transactions made under a Rule 10b5-1 trading plan?

These transactions were not indicated as being made under a Rule 10b5-1 trading plan. The document’s Rule 10b5-1 checkbox was not marked as affirmative, and no footnote describes a pre-arranged trading arrangement governing these reported entries.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Levine Jon R

(Last)(First)(Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD, MASSACHUSETTS 02062

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common stock07/15/2026M30,625A$0(1)21,369,243D
Common stock07/15/2026F10,612(2)D$0.066221,358,631D
Common stock6,684,640IBy the Jon Levine Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units (RSU)(1)07/15/2026M30,625 (4) (4)Common Stock, par value $.001 per share30,625$091,875D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
4. The RSUs were granted on April 15, 2026; the remaining RSUs under this grant will vest in three equal installments on each of October 15, 2026, January 15, 2027 and April 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Jon R. Levine07/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)